Skip to content

Psychopharmacology

ISSN 1432-2072, 0033-3158

637 papers in the library · 20,322 citations · publishing 1971-2026

Papers

Sort Most recent Most cited

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

Psychopharmacology July 26, 2012 André Schmidt, Michael Kometer, Rosilla Bachmann et al. 94 citations

RationaleBoth glutamate and serotonin (5-HT) play a key role in the pathophysiology of emotional biases. Recent studies indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine and the 5-HT receptor agonist psilocybin are implicated in emotion processing. However, as yet, no study has systematically compared their contribution to emotional biases.ObjectivesThis study...

Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

Psychopharmacology June 1, 2012 Adam L. Halberstadt, David E Nichols, Mark A. Geyer 55 citations

Ayahuasca is a psychoactive tea prepared from a combination of plants that contain a hallucinogenic tryptamine and monoamine oxidase inhibitors (MAOIs). Behavioral pattern monitor (BPM) experiments demonstrated that the combination of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and a behaviorally inactive dose of an MAO(A) inhibitor such as harmaline or clorgyline induces biphasic effects on...

DOI: 10.1007/s00213-011-2616-6 (opens in new tab) Full text (opens in new tab) Neuropharmacology Drug metabolism Behavioral effects Pharmacological research

Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.

Psychopharmacology April 2012 Tibor M Brunt, Maarten W Koeter, Raymond J.m. Niesink et al.

Most studies on the subjective effects of ecstasy are based on the assumption that the substance that was taken is 3,4-methylenedioxymethamphetamine (MDMA). However, many tablets sold as ecstasy contain other substances and MDMA in varying doses. So far, few attempts have been made to take this into account while assessing subjective effects. This study aims to link the pharmacological content...

Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.

Psychopharmacology April 2012 Kevin Sean Murnane, Shane Alan Perrine, Brendan James Finton et al.

Considerable evidence indicates that amphetamine derivatives can deplete brain monoaminergic neurotransmitters. However, the behavioral and cognitive consequences of neurochemical depletions induced by amphetamines are not well established. In this study, mice were exposed to dosing regimens of 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (METH), or parachloroamphetamine (PCA)...

The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning.

Psychopharmacology April 2012 Con Stough, Rebecca King, Katherine Papafotiou et al.

This study investigated the acute (3-h) and 24-h post-dose cognitive effects of oral 3,4-methylenedioxymethamphetamine (MDMA), d-methamphetamine, and placebo in a within-subject double-blind laboratory-based study in order to compare the effect of these two commonly used illicit drugs on a large number of recreational drug users. Sixty-one abstinent recreational users of illicit drugs comprised...

MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei.

Psychopharmacology April 2012 Rowan P Ogeil, David J Kennaway, Mark D Salkeld et al.

±3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is a psychoactive drug that has marked effects on the serotonergic system. Serotonergic agonists are known to interact with the circadian pacemaker located in the suprachiasmatic nuclei (SCN). Given changes reported in the behavioral activity rhythm following MDMA treatment, the effects of MDMA on core clock gene (Per1, Per2) and c-fos...

Acute and post-acute behavioral and psychological effects of salvinorin A in humans.

Psychopharmacology March 1, 2012 Peter H. Addy 71 citations

Salvia divinorum has been used for centuries, and nontraditional use in modern societies is increasing. Inebriation and aftereffects of use are poorly documented in the scientific literature. This double-blind, placebo-controlled, randomized study analyzed subjective experiences of salvinorin A (SA) inebriation and consequences of use after 8 weeks. Thirty middle-aged, well-educated,...

AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.

Psychopharmacology March 2012 Torbjörn U C Järbe, Sherrica Tai, Brian J LeMay et al.

The endocannabinoid signaling system (ECS) has been targeted for developing novel therapeutics since ECS dysfunction has been implicated in various pathologies. Current focus is on chemical modifications of the hexahydrocannabinol (HHC) nabilone (Cesamet(®)). To characterize the novel, high-affinity cannabinoid receptor 1 (CB(1)R) HHC-ligand AM2389...

Involvement of the endocannabinoid system in reward processing in the human brain.

Psychopharmacology February 2012 Hendrika H Van Hell, Gerry Jager, Matthijs G. Bossong et al.

Disturbed reward processing in humans has been associated with a number of disorders, such as depression, addiction, and attention-deficit hyperactivity disorder. The endocannabinoid (eCB) system has been implicated in reward processing in animals, but in humans, the relation between eCB functioning and reward is less clear. The current study uses functional magnetic resonance imaging (fMRI) to...

The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Psychopharmacology February 2012 Michelle Carbuto, R Andrew Sewell, Ashley H Williams et al.

Delta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects. This study aims to evaluate the safety of all intravenous THC...

Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats.

Psychopharmacology February 2012 Nobuaki Egashira, Naomi Manome, Kenichi Mishima et al.

Cannabis is a widely used illicit substance. ∆(9)-Tetrahydrocannabinol (THC), the major psychoactive component of cannabis, is known to induce cognitive deficits that closely resemble the impairment observed in schizophrenic patients. We previously reported that THC (6 mg/kg) impairs spatial memory in the eight-arm radial maze, and that this memory disturbance was reversed by the cannabinoid...

Psychoactive drugs and false memory: comparison of dextroamphetamine and delta-9-tetrahydrocannabinol on false recognition

Psychopharmacology 2012 Michael E. Ballard, David A Gallo, Harriet Wit 38 citations

Rationale Several psychoactive drugs are known to influence episodic memory. However, these drugs’ effects on false memory, or the tendency to incorrectly remember nonstudied information, remain poorly understood. Objectives Here, we examined the effects of two commonly used psychoactive drugs, one with memory-enhancing properties (dextroamphetamine; AMP), and another with memory-impairing...

DOI: 10.1007/s00213-011-2374-5 (opens in new tab) Full text (opens in new tab) Amphetamine Cannabinoids Learning and memory Human +2

Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression.

Psychopharmacology January 2012 Lena Wischhof, Michael Koch

Overactivation of serotonin (5-hydroxytryptamine, 5-HT)(2A) receptors causes impulsivity and attentional deficits. Since 5-HT(2A) receptors are known to entertain antagonistic interactions with metabotropic glutamate (mGlu)2/3 receptors, this interaction may provide an alternative target for a novel class of antipsychotics. The study characterizes interactions between 5-HT(2A) and mGlu2/3...

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Psychopharmacology December 1, 2011 Roland R. Griffiths, Matthew W Johnson, William A Richards et al. 938 citations

This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions. Participants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted...

Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.

Psychopharmacology November 2011 Marta Rodríguez‐arias, Concepción Maldonado, Antonio Vidal-Infer et al.

Heavy binge drinking is increasingly frequent among adolescents, while ethanol (EtOH) is often used in combination with 3,4-methylenedioxymethamphetamine (MDMA). The long-lasting effects of intermittent exposure to EtOH and MDMA during adolescence on motor activity, anxiety, and social behavior were evaluated in adult mice. The concentration of brain monoamines in the striatum, cortex, and...

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Psychopharmacology November 2011 Charlotte Klein, Emily Karanges, Adena Spiro et al.

The interactions between Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) during chronic treatment, and at equivalent doses, are not well characterised in animal models. The aim of this study is to examine whether the behavioural effects of THC, and blood and brain THC levels are affected by pre-treatment with equivalent CBD doses. Adolescent rats were treated with ascending daily THC...

Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication

Psychopharmacology October 5, 2011 Eef L. Theunissen, Gerold F. Kauert, Stefan W. Toennes et al. 82 citations

RATIONALE: Experienced cannabis users demonstrate tolerance to some of the impairing acute effects of cannabis. OBJECTIVES: The present study investigates whether event-related potentials (ERPs) differ between occasional and heavy cannabis users after acute Δ9-tetrahydrocannabinol (THC) administration, as a result of tolerance. METHODS: Twelve occasional and 12 heavy cannabis users participated...

DOI: 10.1007/s00213-011-2479-x (opens in new tab) Full text (opens in new tab) Cannabidiol Delta-9-tetrahydrocannabinol Dronabinol Crossover study +6

delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.

Psychopharmacology October 2011 Laura E Wise, Stephen A Varvel, Dana E Selley et al.

Cannabis users display a constellation of withdrawal symptoms upon drug discontinuation, including sleep disturbances, irritability, and possibly memory deficits. In cannabinoid-dependent rodents, the CB(1) antagonist rimonabant precipitates somatic withdrawal and enhances forskolin-stimulated adenylyl cyclase activity in cerebellum, an effect opposite that of acutely administered...

Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.

Psychopharmacology October 2011 Una D. Mccann, Robert R Edwards, Michael T Smith et al.

(±)3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has potential to damage brain serotonin (5-HT) neurons in humans. Brain 5-HT neurons play a role in pain modulation, yet little is known about long-term effects of MDMA on pain function. Notably, MDMA users have been shown to have altered sleep, a phenomenon that can lead to altered pain modulation. This study...

MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid

Psychopharmacology September 27, 2011 Wendy M. Bosker, Kim P. C. Kuypers, Silke Conen et al. 32 citations

RATIONALE: Experimental research has shown that 3,4-methylenedioxymethamphetamine (MDMA) can improve some psychomotor driving skills when administered during the day. In real life, however, MDMA is taken during the night, and driving may likely occur early in the morning after a night of "raving" and sleep loss. OBJECTIVES: The present study assessed the effects of MDMA on road-tracking and...

Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.

Psychopharmacology September 15, 2011 Agnieszka Nikiforuk, Piotr Popik

Rationale: Prefrontal cortical dysfunctions, including an impaired ability to shift perceptual attentional set, are core features of schizophrenia. Nevertheless, the effectiveness of second-generation antipsychotic drugs in treating specific prefrontal dysfunctions remains equivocal. Objectives: To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated...

DOI: 10.1007/s00213-011-2487-x (opens in new tab) Full text (opens in new tab) Ketamine Animals Rats, sprague-dawley Disease models, animal +10

Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.

Psychopharmacology September 2011 Masakuni Horiguchi, Mei Huang, Herbert Y. Meltzer

Subchronic administration to rodents of the N-methyl-D-aspartate non-competitive antagonist, phencyclidine (PCP), impairs novel object recognition (NOR). Atypical antipsychotic drugs (APDs) reverse the effects of subchronic PCP on NOR. The effect of metabotropic glutamate₂/₃ receptor (mGlu₂/₃) agonists upon NOR is unknown. We tested the hypotheses that the mGlu₂/₃ agonist, LY379268, by itself,...

Pharmacology of ayahuasca administered in two repeated doses

Psychopharmacology August 12, 2011 Rafael G. Dos Santos, Eva Grasa, Marta Valle et al. 139 citations

RationaleAyahuasca is an Amazonian tea containing the natural psychedelic 5-HT(2A/2C/1A) agonist N,N-dimethyltryptamine (DMT). It is used in ceremonial contexts for its visionary properties. The human pharmacology of ayahuasca has been well characterized following its administration in single doses.ObjectivesTo evaluate the human pharmacology of ayahuasca in repeated doses and assess the...

DOI: 10.1007/s00213-011-2434-x (opens in new tab) Ayahuasca Placebo Crossover study Pharmacology +3

Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine (“Ecstasy”)/polydrug users

Psychopharmacology August 1, 2011 Adrian P. Burgess, Louise Venables, Helena Jones et al. 26 citations

Objectives Ecstasy is a recreational drug whose active ingredient, 3,4-methylenedioxymethamphetamine (MDMA), acts predominantly on the serotonergic system. Although MDMA is known to be neurotoxic in animals, the long-term effects of recreational Ecstasy use in humans remain controversial but one commonly reported consequence is mild cognitive impairment particularly affecting verbal episodic...

Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions.

Psychopharmacology August 2011 Daniel L Albaugh, Jennifer A Rinker, Michael H. Baumann et al.

The abuse potential of a given drug may be mediated by both its rewarding and aversive effects, the latter of which are often far less characterized. Using the conditioned taste-aversion (CTA) preparation, the present experiments examined changes in the aversive effects of the commonly used recreational drug MDMA following repeated drug exposures. Experiment 1 used three varying doses of MDMA...